HAC is dedicated to funding and supporting research that will lead to a better understanding – and better treatment – of Amyloidosis. We partner with other like-minded organizations, including Regroupement québécois des maladies orphelines (RQMO) to provide financial support for trainees and early career (within the first 5 years) investigators who are studying transthyretin amyloidosis.

To ensure we are funding the best and brightest in the field, we have established an independent Scientific Advisory Committee of experts from the medical and scientific community to guide the research process, including program development and peer reviews.

Along with representatives from HAC and RQMO, the committee includes:

  • Dr. Vera Bril (Neurologist, Toronto, ON)
  • Dr. Kristine Chapman (Vancouver, BC)
  • Dr. Diego Delgado (Cardiologist, Toronto, ON)
  • Dr. Nowell Fine (Cardiologist, Calgary, AB)
  • Dr. Angela Genge (Neurologist, Montreal, QC)
  • Dr. Francois Tournoux (Cardiologist, Montreal, QC)

Click here for more information on the latest research projects that we are funding and supporting.

Sign up to Stay in Touch!

Get important updates, including Canadian-focused news and information about ATTR, delivered to your inbox.

11 + 1 =

*By submitting this form, you are consenting to receive emails from Hereditary Amyloidosis Canada. You can revoke your consent to receive emails at any time by using the unsubscribe link, found at the bottom of every email.

Share This